EPIDAREX IS A TRANSATLANTIC VENTURE CAPITAL FIRM LED BY A DIVERSE TEAM OF EARLY-STAGE INVESTORS BUILDING BREAKTHROUGH LIFE SCIENCE COMPANIES IN EMERGING HUBS
We are trusted partners to our founders and co-investors. We use our deep scientific and industry networks to create exceptional value and shared success.
Epidarex builds the extraordinary.
Recent News
Dunad CEO Pearl Huang interviewed in Nature Reviews Drug Discovery
Please see the article here for a Q+A interview with Dunad CEO Pearl Huang in Nature Reviews Drug Discovery.
NodThera Announces Positive Phase 1 Study Readouts for the NLRP3 Inflammasome Inhibitors NT-0796 and NT-0249
NT-0796 successfully completes Phase 1 study, demonstrating blood-brain barrier penetration and reduced inflammatory biomarkers supporting advancement in neuroinflammatory and peripheral inflammatory diseases Second